70.31

4.47% 3.01

Halozyme Therapeutics Inc (HALO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HALO Giù? Forum Previsione

Precedente Chiudi:

$67.30

Aprire:

$67.71

Volume 24 ore:

2.84M

Relative Volume:

1.28

Capitalizzazione di mercato:

$8.27B

Reddito:

$947.36M

Utile/perdita netta:

$392.47M

Rapporto P/E:

23.28

EPS:

3.02

Flusso di cassa netto:

$392.71M

1 W Prestazione:

+2.09%

1M Prestazione:

+5.67%

6M Prestazione:

+30.59%

1 anno Prestazione:

+46.45%

Intervallo 1D:

$67.16

$70.35

Intervallo di 1 settimana:

$67.02

$70.35

Portata 52W:

$47.50

$79.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Nome

Halozyme Therapeutics Inc

Settore

Healthcare (1131)

Industria

Biotechnology (631)

Telefono

(858) 794-8889

Indirizzo

12390 EL CAMINO REAL, SAN DIEGO, CA

Dipendente

350

Cinguettio

@halozymeinc

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

HALO's Discussions on Twitter

Confronta HALO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HALO Halozyme Therapeutics Inc	70.31	7.91B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-04	Downgrade	Goldman	Neutral → Sell
2025-10-14	Aggiornamento	Leerink Partners	Underperform → Market Perform
2025-08-06	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-07-10	Ripresa	Goldman	Neutral
2025-05-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-05-13	Downgrade	Leerink Partners	Market Perform → Underperform
2024-10-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-09-19	Downgrade	JP Morgan	Overweight → Neutral
2024-06-07	Downgrade	Piper Sandler	Overweight → Neutral
2024-02-29	Iniziato	TD Cowen	Outperform
2023-07-24	Downgrade	Goldman	Buy → Neutral
2023-07-24	Iniziato	H.C. Wainwright	Buy
2023-05-10	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-03-27	Ripresa	Berenberg	Buy
2023-03-16	Downgrade	SVB Securities	Outperform → Market Perform
2022-12-21	Ripresa	Morgan Stanley	Overweight
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-09-09	Iniziato	Morgan Stanley	Overweight
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-06-14	Iniziato	Evercore ISI	Outperform
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-11	Downgrade	Piper Sandler	Overweight → Neutral
2021-01-21	Reiterato	The Benchmark Company	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-07-01	Iniziato	The Benchmark Company	Buy
2020-02-05	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-01-09	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-08	Iniziato	Goldman	Buy
2019-11-05	Aggiornamento	Barclays	Underweight → Equal Weight
2018-10-19	Ripresa	Piper Jaffray	Neutral
2018-05-11	Downgrade	Barclays	Equal Weight → Underweight
2018-01-24	Iniziato	Goldman	Neutral
2017-10-16	Reiterato	Piper Jaffray	Overweight
2017-01-06	Downgrade	Citigroup	Buy → Neutral
2016-11-03	Iniziato	Deutsche Bank	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-11-18	Iniziato	Citigroup	Buy
2015-09-22	Iniziato	Barclays	Overweight
2015-06-22	Reiterato	JP Morgan	Overweight
2015-03-03	Reiterato	UBS	Buy
2015-02-18	Reiterato	MLV & Co	Buy
2015-01-08	Reiterato	MLV & Co	Buy

Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

Jan 02, 2026

Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn

Jan 02, 2026

Jan 01, 2026

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail

Jan 01, 2026

Dec 31, 2025

How Halozyme Therapeutics Inc. (HALO) Affects Rotational Strategy Timing - Stock Traders Daily

Dec 31, 2025

Here's What Analysts Think About Halozyme Therapeutics (HALO) - Finviz

Dec 31, 2025

Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Insider Monkey

Dec 31, 2025

Dec 29, 2025

Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO) - 富途牛牛

Dec 29, 2025

Halozyme Therapeutics (NASDAQ:HALO) Nasdaq Composite Biopharma Platform - Kalkine Media

Dec 29, 2025

Zacks Research Brokers Increase Earnings Estimates for HALO - MarketBeat

Dec 29, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages - MarketBeat

Dec 29, 2025

Dec 28, 2025

Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Dec 28, 2025

Dec 27, 2025

Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Dec 27, 2025

Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Dec 27, 2025

Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Dec 27, 2025

Dec 25, 2025

Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More - Insider Monkey

Dec 25, 2025

Dec 24, 2025

Halozyme Therapeutics CEO sells $1.14 million in stock - Investing.com

Dec 24, 2025

Dec 23, 2025

Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily

Dec 23, 2025

27,468 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Monument Capital Management - MarketBeat

Dec 23, 2025

Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Yahoo Finance

Dec 23, 2025

Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent InjunctionWhat's Changed - Yahoo Finance

Dec 23, 2025

Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside? - Sahm

Dec 23, 2025

Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Yahoo Finance

Dec 23, 2025

Dec 22, 2025

EBITDA per share of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView — Track All Markets

Dec 22, 2025

Dec 21, 2025

Halozyme Therapeutics (BIT:1HALO) Price Target Decreased by 13.37% to 59.51 - Nasdaq

Dec 21, 2025

Halozyme Therapeutics (MEX:HALO) EV-to-OCF : 13.06 (As of Dec. 23, 2025) - GuruFocus

Dec 21, 2025

Halozyme Therapeutics (STU:RV7) EV-to-OCF : 13.50 (As of Dec. 22, 2025) - GuruFocus

Dec 21, 2025

Why Halozyme Therapeutics (HALO) Is Up 8.3% After FDA Nod And Patent Win In Lung Cancer - Sahm

Dec 21, 2025

Why Halozyme Therapeutics Inc. stock remains undervalued2025 Price Momentum & AI Powered Market Trend Analysis - Улправда

Dec 21, 2025

Congress Asset Management Co. Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Dec 21, 2025

Dec 20, 2025

Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correctionMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда

Dec 20, 2025

(HALO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com

Dec 20, 2025

Market Fear: Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correctionJuly 2025 Opening Moves & Low Volatility Stock Suggestions - ulpravda.ru

Dec 20, 2025

Dec 19, 2025

Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock - MarketBeat

Dec 19, 2025

HALO (Halozyme Therapeutics) EV-to-OCF : 14.29 (As of Dec. 20, 2025) - GuruFocus

Dec 19, 2025

COO Caudill Acquires 5,063 Of Halozyme Therapeutics Inc [HALO] - TradingView — Track All Markets

Dec 19, 2025

HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq

Dec 19, 2025

Is Halozyme Therapeutics Inc. stock vulnerable to regulatory risksWeekly Stock Summary & Community Trade Idea Sharing - Улправда

Dec 19, 2025

Breakouts Watch: Why Halozyme Therapeutics Inc. stock could see breakout soonJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - Улправда

Dec 19, 2025

Halozyme Therapeutics Stock (HALO) Opinions on FDA Approval and Legal Win - Quiver Quantitative

Dec 19, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

Dec 19, 2025

Halozyme Therapeutics' (HALO) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 19, 2025

HALO Analyst Rating: HC Wainwright & Co. Reiterates Buy Rating | - GuruFocus

Dec 19, 2025

Halozyme Therapeutics receives composite rating upgrade - MSN

Dec 19, 2025

Why Halozyme Therapeutics Inc. (RV7) stock is a must watch tickerPortfolio Return Report & AI Optimized Trading Strategy Guides - DonanımHaber

Dec 19, 2025

Dec 18, 2025

FDA approves Halozyme’s RYBREVANT FASPRO for EGFR-mutated lung cancer - Investing.com Nigeria

Dec 18, 2025

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PR Newswire

Dec 18, 2025

Dec 17, 2025

Where is Halozyme Therapeutics (HALO) Headed According to Analysts? - MSN

Dec 17, 2025

Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics - StreetInsider

Dec 17, 2025

Dec 16, 2025

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga

Dec 16, 2025

Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang - Sahm

Dec 16, 2025

Dec 15, 2025

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha

Dec 15, 2025

Dec 14, 2025